A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease-Reference-Cited by-同舟云学术

A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease

Published:2017-10 Issue: Volume:812 Page:82-90
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Yuan Ziyue,Li Dongfang,Feng Peng,Xue Guofang,Ji Chenhui,Li Guanglai,Hölscher Christian

Funder

Cure Parkinson's Trust UK

Publisher

Elsevier BV

Subject

Pharmacology

Reference63 articles.

1. The GDNF family: signalling, biological functions and therapeutic value;Airaksinen;Nat. Rev. Neurosci.,2002

2. GDNF, NGF and BDNF as therapeutic options for neurodegeneration;Allen;Pharmacol. Ther.,2013

3. Exenatide and the treatment of patients with Parkinson's disease;Aviles-Olmos;J. Clin. Investig.,2013

4. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease;Aviles-Olmos;J. Parkinson's Dis.,2014

5. Parkinson's disease, insulin resistance and novel agents of neuroprotection;Aviles-Olmos;Brain,2013

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond insulin: The Intriguing role of GLP-1 in Parkinson's disease;European Journal of Pharmacology;2024-11

2. Current Therapeutic Options and Repurposed Drugs for Neurodegeneration;Advances in Diagnostics and Immunotherapeutics for Neurodegenerative Diseases;2024-07-28

3. From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists;Molecular Biology Reports;2024-07-23

4. Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut;Peptides;2024-06

5. Cholecystokinin (CCK): a neuromodulator with therapeutic potential in Alzheimer’s and Parkinson’s disease;Frontiers in Neuroendocrinology;2024-04